Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on

Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 29, 2020

June 29, 2020 New York Cellectis S.A. held its Annual Shareholders General Meeting (Euronext Growth:

ALCLS Nasdaq: CLLS) was held on June 29, 2020 at its head office in Paris, France.

At the meeting, during which more than 63% of voting

rights were exercised, Resolutions 1 through 22, and Resolutions 26 through 28 were adopted. Resolutions 23, 24, 25 and 29 were rejected. The detailed results of the vote and the resolutions are available on the company s website:

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the

concept of off-the-shelf and ready-to-use gene-edited CAR

T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for

multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq

Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social

media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark

For further information, please contact:

Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com

Caitlin Kasunich, KCSA Strategic

Communications, 212-896-1241, ckasunich@kcsa.com

Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,